PDF(Pubmed)
Abstract：
Preclinical evidence has firmly established a bidirectional interaction among the lung, gut, and gut microbiome. There are many complex communication pathways between the lung and intestine, which affect each other\'s balance. Some metabolites produced by intestinal microorganisms, intestinal immune cells, and immune factors enter lung tissue through blood circulation and participate in lung immune function. Altered gut-lung-microbiome interactions have been identified in rodent models and humans of several lung diseases such as pulmonary fibrosis, chronic obstructive pulmonary disease, lung cancer, asthma, etc. Emerging evidence suggests that microbial therapies can prevent and treat respiratory diseases, but it is unclear whether this association is a simple correlation with the pathological mechanisms of the disease or the result of causation. In this review, we summarize the complex and critical link between the gut microbiota and the lung, as well as the influence and mechanism of the gut microbiota on respiratory diseases, and discuss the role of interventions such as prebiotics and fecal bacteria transplantation on respiratory diseases. To provide a reference for the rational design of large-scale clinical studies, the direct application of microbial therapy to respiratory-related diseases can reduce the incidence and severity of diseases and accompanying complications.
摘要：
临床前的证据已经确定了肺之间的双向相互作用，gut,gut和肠道微生物组。肺和肠之间有许多复杂的交流途径，这会影响彼此的平衡。一些由肠道微生物产生的代谢产物,肠道免疫细胞，免疫因子通过血液循环进入肺组织参与肺免疫功能。已经在啮齿动物模型和人类中发现了改变的肠-肺-微生物组相互作用，例如肺纤维化，慢性阻塞性肺疾病,肺癌,哮喘,等。新的证据表明，微生物疗法可以预防和治疗呼吸系统疾病，但尚不清楚这种关联是否与疾病的病理机制或因果关系简单相关。在这次审查中,我们总结了肠道菌群和肺之间复杂而关键的联系，以及肠道菌群对呼吸系统疾病的影响和机制，探讨益生元、粪菌移植等干预措施对呼吸系统疾病的作用。为大规模临床研究的合理设计提供参考,将微生物疗法直接应用于呼吸系统相关疾病可以降低疾病的发生率和严重程度以及伴随的并发症。
